JP2020500168A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500168A5
JP2020500168A5 JP2019521720A JP2019521720A JP2020500168A5 JP 2020500168 A5 JP2020500168 A5 JP 2020500168A5 JP 2019521720 A JP2019521720 A JP 2019521720A JP 2019521720 A JP2019521720 A JP 2019521720A JP 2020500168 A5 JP2020500168 A5 JP 2020500168A5
Authority
JP
Japan
Prior art keywords
composition
composition according
fraction
excipient
granule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019521720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500168A (ja
JP7197474B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/077030 external-priority patent/WO2018077815A1/en
Publication of JP2020500168A publication Critical patent/JP2020500168A/ja
Publication of JP2020500168A5 publication Critical patent/JP2020500168A5/ja
Priority to JP2022165319A priority Critical patent/JP2023011659A/ja
Application granted granted Critical
Publication of JP7197474B2 publication Critical patent/JP7197474B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019521720A 2016-10-24 2017-10-23 分散性組成物 Active JP7197474B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022165319A JP2023011659A (ja) 2016-10-24 2022-10-14 分散性組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (en) 2016-10-24 2017-10-23 Dispersible compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022165319A Division JP2023011659A (ja) 2016-10-24 2022-10-14 分散性組成物

Publications (3)

Publication Number Publication Date
JP2020500168A JP2020500168A (ja) 2020-01-09
JP2020500168A5 true JP2020500168A5 (https=) 2020-12-10
JP7197474B2 JP7197474B2 (ja) 2022-12-27

Family

ID=60262899

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019521720A Active JP7197474B2 (ja) 2016-10-24 2017-10-23 分散性組成物
JP2022165319A Withdrawn JP2023011659A (ja) 2016-10-24 2022-10-14 分散性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022165319A Withdrawn JP2023011659A (ja) 2016-10-24 2022-10-14 分散性組成物

Country Status (21)

Country Link
US (2) US11065198B2 (https=)
EP (2) EP4248947A3 (https=)
JP (2) JP7197474B2 (https=)
KR (2) KR20190073450A (https=)
CN (1) CN110191704A (https=)
CA (1) CA3039562A1 (https=)
DK (1) DK3528791T3 (https=)
ES (1) ES2970870T3 (https=)
FI (1) FI3528791T3 (https=)
HR (1) HRP20240118T1 (https=)
HU (1) HUE064823T2 (https=)
LT (1) LT3528791T (https=)
MA (1) MA46563B1 (https=)
MX (1) MX2019004767A (https=)
PL (1) PL3528791T3 (https=)
PT (1) PT3528791T (https=)
RS (1) RS65159B1 (https=)
SI (1) SI3528791T1 (https=)
SM (1) SMT202400060T1 (https=)
TW (1) TWI821163B (https=)
WO (1) WO2018077815A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるhivを治療する方法
CN115397422A (zh) 2019-11-29 2022-11-25 西皮欧生命科学有限公司 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
KR101140785B1 (ko) 2002-08-09 2012-05-03 얀센 파마슈티카 엔.브이. 4-〔〔4-〔〔4-(2-시아노에테닐)-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
ATE508748T1 (de) 2004-09-02 2011-05-15 Janssen Pharmaceutica Nv Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
EP2040671B1 (en) 2006-06-23 2018-01-24 Janssen Sciences Ireland UC Aqueous suspensions of tmc278
US20160346198A1 (en) 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine
CA2949094A1 (en) * 2014-05-16 2015-11-19 Vivus, Inc. Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use

Similar Documents

Publication Publication Date Title
JP2020500168A5 (https=)
US8309126B2 (en) Dispersible bosentan tablet
FI3265084T3 (fi) Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
TWI583384B (zh) 包含4-胺基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸鹽單水合物之醫藥組合物
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
JP2006516570A5 (https=)
JP2014533733A5 (https=)
JP2015511621A5 (https=)
RU2019122414A (ru) Антивирусные алифатические сложноэфирные пролекарства тенофовира
NZ627963A (en) Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase
US20150104511A1 (en) Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine
JP2019536812A5 (https=)
FI3528791T3 (fi) Dispergoituvia koostumuksia
JP2010520891A (ja) ネビラピンの徐放性製剤
HRP20251043T1 (hr) Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća
JP2015534985A5 (https=)
WO2021091498A1 (en) Pharmaceutical compositions comprising tenofovir and emtricitabine
JP2018184382A (ja) エゼチミブ含有錠剤およびその製法
ZA202200331B (en) Naltrexone formulation
EP3518935A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
JP2018184381A (ja) エゼチミブ含有錠剤およびその製法
JP6965497B2 (ja) レボセチリジン固形製剤
WO2013154512A1 (en) Pharmaceutical formulations comprising dexibuprofen
JP2010516712A5 (https=)
ES2875405T3 (es) Composición farmacéutica que comprende darunavir y método para su preparación